LinkResPet (LRSV) Launches E-commerce Site, Delivering CBD

New Post Public Reply Private Reply Replies (0) Message Board
Lee Adams trooperstocks #28
298
LinkResPet (LRSV) Launches E-commerce Site, Delivering CBD For Pets Across North America

KINGTON, United Kingdom, May 15, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- LinkResPet, a subsidiary of Link Reservations Inc. (OTC: LRSV), a company providing Cannabidiol (CBD) products especially tailored for pets, announces the launch of its e-commerce site. Consumers in the US and Canada will now be able to purchase LinkResPet’s CBD products for dogs, cats and horses on http://www.linkrespet.com.

“This is a big step, as it cements our foothold in the North American market. Having an online shop is vital for our brand and more importantly our customers, who are predominantly e-commerce native. Developing our e-commerce site certainly helps us reach more customers – particularly those who don’t have pet shops carrying CBD product near them – but in the current market, digital represents a big chunk of retailing activity in the sector and we are determined to be part of it!”

With the new e-shop, the Company is intending to roll a subscription option, allowing customers to get a recurring package of LinkResPet CBD products for their pets and ensuring they never run out. Additionally, schemes that allow users to curate their own CBD product boxes are also being considered.

To order LinkResPet’s CBD products for dogs, cats and horses please visit: http://www.linkrespet.com

About LinkResPet and Link Reservations Inc.
LinkResPet, a subsidiary of Link Reservations Inc (OTC: LRSV), is CBD Petcare provider dedicated to improving the health and life conditions of pets worldwide. Developing and marketing hemp-based CBD products for cats, dogs and horses, Link Reservations Inc is currently present in Europe and in the US. A pioneer in the area, LinkResPet products can be found online on: http://www.linkrespet.com

Forward-Looking Statements & Disclaimers:
The information in this Press Release includes certain "forward-looking" statements within the meaning of the Safe Harbor provisions of Federal Securities Laws, as that term is defined in section 27a of the United States Securities Act of 1933, as amended, and section 21e of the United States Securities Exchange Act of 1934, as amended. Statements in this document, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Investors are cautioned that such statements are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release, and the Company undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

LinkResPet/Link Reservations Inc.
61 Bridge Street
Kington
Herefordshire HR5 3DJ
United Kingdom
http://www.linkrespet.com
+44 330 808 0897
info@linkreservationsinc.com

Link Reservations Inc (LRSV) Stock Research Links

LRSV Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 21

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 10

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 10

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 20

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 14

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 22

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 18

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Boussard & Gavaudan Holding Limited: NAV Insights

Updated Category News Views 74

Boussard & Gavaudan Holding Limited: Overview Boussard & Gavaudan Holding Limited is an investment company focused on generating substantial returns for its shareholders through strategic investments and active management. The company has garnered attention due to its robust performance in the market. Here, we delve into the estimated Net Asset Value (NAV) and key...

Continue Reading
Erwin Chemerinsky to Explore Government Power Dynamics

Updated Category News Views 195

Erwin Chemerinsky to Discuss Power Among Government Branches One of the leading experts in constitutional law, Erwin Chemerinsky, will be the keynote speaker for an upcoming lecture at the University of Houston Law Center. His lecture, titled "Constitutional Separation of Powers," promises to provide insightful exploration into the allocation of power among the...

Continue Reading
Cytokinetics' Future Looks Bright with H.C. Wainwright Rating

Updated Category News Views 72

Cytokinetics got buzzed about back when H.C. Wainwright slapped a strong Buy rating on 'em, setting a price target of $90 per share. Analysts were all in, believing aficamten could really shake things up for obstructive Hypertrophic Cardiomyopathy (oHCM) patients. Remember that SEQUOIA-HCM Phase 3 trial? Yeah, that’s where they showed some serious cardiac remodeling...

Continue Reading
Century Therapeutics Enhances Executive Team with Key Changes

Updated Category News Views 234

Alright, let's cut to the chase: Century Therapeutics, Inc. (NASDAQ: IPSC) is shuffling its deck with some heavyweight appointments—new blood, new vibes. Morgan Conn, Ph.D., struts in as Chief Financial Officer while Chad Cowan, Ph.D., dons the Chief Scientific Officer cape. This isn't just a warm body swap; it's a strategic play aiming to steer the company deeper into...

Continue Reading
BitMine Immersion Technologies Stock and Crypto Surge Explained

Updated Category News Views 216

The Rise of BitMine Immersion Technologies Inc. Shares of BitMine Immersion Technologies Inc. (NASDAQ: BMNR) are experiencing upward momentum as the company shares recent achievements. This crypto treasury company has reported significant increases in its cryptocurrency assets, which have garnered attention across financial markets. Recent Developments in Crypto Holdings...

Continue Reading